Transgene and BioInvent announced that preclinical studies of their oncolytic virus BT-001 will be presented at the AACR Annual Meeting 2022. This innovative therapy targets CTLA-4, showing robust anti-tumoral activity and improved safety compared to traditional treatments. Results indicate BT-001 effectively treats resistant 'cold tumors' and enhances regulatory T cell depletion. The Phase I/IIa clinical study is ongoing, assessing BT-001 alone and with pembrolizumab. Initial data is expected in early 2022.
Transgene and BioInvent announced in a press release that their co-developed product, BT-001, has shown promising preclinical proof-of-concept data, published in the Journal for ImmunoTherapy of Cancer. The study indicates that BT-001 may provide superior therapeutic benefits over conventional anti-CTLA-4 antibodies, with significant reductions in systemic toxicity and enhanced efficacy against ‘cold tumors’. Ongoing Phase 1/2a trials in Europe aim to demonstrate BT-001's effectiveness against solid tumors, with initial data expected in H1 2022.
BioInvent (BINV) and Transgene announced promising preclinical data for their oncolytic virus BT-001, designed to combat solid tumors. The findings indicate significant intratumoral expression of an immune checkpoint inhibitor and strong anti-tumoral activity across various models. Currently in a Phase I/IIa trial, BT-001 aims to enhance treatment efficacy while minimizing systemic exposure. Initial results are expected in the first half of 2022, showcasing BT-001's potential role in cancer immunotherapy.
Transgene and BioInvent announce the presentation of new preclinical data on their BT-001 oncolytic virus at the upcoming Society for Immunotherapy of Cancer (SITC2021) in Washington, D.C., on November 13, 2021. BT-001 is developed to enhance antitumor response while improving safety by targeting the tumor microenvironment. The ongoing Phase I/IIa study in Europe and the U.S. is progressing well, assessing BT-001 as a monotherapy and in combination with pembrolizumab for solid tumors. Initial Phase I results are anticipated in H1 2022.